Bellerophon Therapeutics, Inc.
DelistedCIK 1600132fmd_0KJ6VVRBBNGGNPSG9VMJJ50QNAManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Sep 30, 2023, 41 periods
Latest annual · FY2022
Millions- Operating income
- (22)
- Net income
- (20)
Latest quarter · Q3 FY2023
Millions- Total revenues
- 0
- Operating income
- (2)
- Net income
- (2)
Key stats
Open AnalysisCompound annual growth
- Net income, 5 yearsFY2017 to FY2022
- n/m
Bellerophon Therapeutics, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2022 | FY2021 | Change | Source |
|---|---|---|---|---|
| Operating income | -$22.4 million | -$20.2 million | 10-K 2023-03-31 · proof | |
| Net income | -$19.8 million | -$17.8 million | 10-K 2023-03-31 · proof | |
| Cash from operating activities | -$17.8 million | -$22.8 million | 10-K 2023-03-31 · proof | |
| Total assets | $7.9 million | $26.9 million | -70.5% | 10-K 2023-03-31 · proof |
| Total liabilities | $5.4 million | $5.3 million | +2.8% | 10-K 2023-03-31 · proof |
| Cash and cash equivalents | $6.9 million | $24.7 million | -72% | 10-K 2023-03-31 · proof |
- What was Bellerophon Therapeutics, Inc.'s operating income in fiscal 2022?
- Bellerophon Therapeutics, Inc. reported operating income of -$22.4 million for fiscal 2022 (the year ended Dec 31, 2022), against -$20.2 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2023. SEC
- What was Bellerophon Therapeutics, Inc.'s net income in fiscal 2022?
- Bellerophon Therapeutics, Inc. reported net income of -$19.8 million for fiscal 2022 (the year ended Dec 31, 2022), against -$17.8 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2023. SEC
- What was Bellerophon Therapeutics, Inc.'s cash from operating activities in fiscal 2022?
- Bellerophon Therapeutics, Inc. reported cash from operating activities of -$17.8 million for fiscal 2022 (the year ended Dec 31, 2022), against -$22.8 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2023. SEC
- What are Bellerophon Therapeutics, Inc.'s total assets?
- As of Dec 31, 2022, Bellerophon Therapeutics, Inc. reported total assets of $7.9 million, against $26.9 million a year earlier (-70.5%). Source: the 10-K filed with the SEC on Mar 31, 2023. SEC
- What are Bellerophon Therapeutics, Inc.'s total liabilities?
- As of Dec 31, 2022, Bellerophon Therapeutics, Inc. reported total liabilities of $5.4 million, against $5.3 million a year earlier (+2.8%). Source: the 10-K filed with the SEC on Mar 31, 2023. SEC
- What are Bellerophon Therapeutics, Inc.'s cash and cash equivalents?
- As of Dec 31, 2022, Bellerophon Therapeutics, Inc. reported cash and cash equivalents of $6.9 million, against $24.7 million a year earlier (-72%). Source: the 10-K filed with the SEC on Mar 31, 2023. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1600132&period_type=annual&limit=5"Information only, not investment advice.